



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 1-4-010

Signature: Aboy Bergie Co

(Abby Berghella)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

John F. Shanley

Serial No.:

10/824,124

Art Unit:

3731

Filed:

April 13, 2004

Examiner:

Unassigned

For:

EXPANDABLE MEDICAL DEVICE WITH S-SHAPED BRIDGING ELEMENTS

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

- 1. Enclosures accompanying this Information Disclosure Statement are:
  - 1a. A PTO-Form 1449 listing all patents, publications, applications, or other information submitted for consideration by the office.
  - 1b. A legible copy of:

Ш	-ach	pub.	licati	on a	and	toreign	patent	re	tere	ence	٠,
---	------	------	--------	------	-----	---------	--------	----	------	------	----

- ☐ Each publication or that portion which caused it to be listed on the PTO-1449;
- For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion:

01/09/2006 DEMMANU1 00000014 503100 10824124

		all other information or portion which caused it to be listed on the PTO-1449.
2.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
		☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
		Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
		☐ Before the mailing of the first Office action on the merits;
		Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3.	⊠	This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.
	3a.	The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
	3b.	□ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
		⊠ enclosed
4.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.
		The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:
		enclosed.
	The Ce	rtification Statement in Item 5 below is applicable.
5.		Certification Statement (applicable if Item 3a or Item 4 is checked)
	5a.	In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	5b.	Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not <b>received</b> by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

	5c.	Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not <b>received</b> by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
6.		This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).
	6a.	A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
	6b.	Copies of publications listed on Form PTO-1449 from prior application Serial No., filed on , of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
	6c.	☐ Copies of the foreign patents and publications listed on Form PTO-1449 are provided herewith.
7.		This is a Supplemental Information Disclosure Statement.
	7a.	This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .
8.		In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:
	8a.	satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
	8b.	set forth in the application.
	8c.	enclosed as an attachment hereto.
9.	$\boxtimes$	The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Conor Medsystems, Inc. Deposit Account No. 50-3100.

10. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date: January 4, 2006

Cindy A. Lynch Reg. No. 38,699 Conor Medsystems, Inc. 1003 Hamilton Court Menlo Park, CA 94025

(650) 614-4100

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/824,124			
Filing Date	April 13, 2004			
First Named Inventor	John F. Shanley			
Art Unit	3731			
Examiner Name	Bui, Vy Q.			
Attorney Docket Number	P003 C5			

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		Number-Kind Code <sup>2 (d known)</sup>	_		riguies Appear
		<sup>US-</sup> 20020022876		Richter et al.	
		<sup>US-</sup> 5948016		Jang	
		<sup>US-</sup> 6123721		Jang	
		<sup>US-</sup> 6200334		Jang	
		<sup>US-</sup> 6231598		Berry et al.	
		<sup>US-</sup> 6309414		Rolando et al.	
		<sup>US-</sup> 6770088		Jang	
		<sup>US-</sup> 6773455		Allen et al.	
		<sup>US-</sup> 6783543		Jang	
		US-			
<u> </u>		US-			
		US-		·	***************************************
	l	US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear				
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	,		T <sup>6</sup>			
						$ldsymbol{ld}}}}}}$			

Evaminor		<del></del>
Examiner	Date	
Signature	Considered	
		Ĭ

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^3\)Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^6\)Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.